Radius Health, Inc. and 3M Drug Delivery Systems announced an agreement to collaborate on the development of a transdermal delivery option for BA058, Radius’ PTHrP analog, for the treatment of osteoporosis.
Nanoscale antennas hold out the promise of higher resolution optical imaging of nano objects, including proteins and DNA molecules, and converting solar energy into electricity at very high efficiencies.
The introduction of a telephoto lens for Insitec laser diffraction process systems from Malvern Instruments enables the on-line measurement of larger particles.
Daiichi Sankyo Company, Limited launched its measles and rubella vaccine, Kitasato Daiichi Sankyo (freeze-dried live attenuated measles and rubella combined vaccine), in Japan.
Siemens Healthcare Diagnostics announces that it has received FDA clearance to market its IMMULITE 2000 XPi Immunoassay System in the United States.
The lists of potential side effects that accompany prescription drugs have ballooned in size, averaging 70 reactions per drug, a number that can overwhelm physicians trying to select suitable treatments for their patients.
Accelrys, Inc., a leading scientific enterprise R&D software and services company, announced that its subsidiary, Accelrys Software Inc., has acquired privately-held Contur Software AB.
Canadian drugmaker Valeant Pharmaceuticals International Inc. said it will acquire Lithuanian specialty pharmaceutical company AB Sanitas in a two-stage deal worth $441.3 million in cash.
Scientists have synthesized of a rare natural product isolated from the bark of a plant used in traditional medicine, an advance that may lead to alternatives to narcotic pain treatments.
Data evaluating the long-term efficacy and safety of Tribenzor (olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide) in patients with hypertension aged 65 years and older showed that the triple therapy was well-tolerated and effective in maintaining the blood pressure reductions, regardless of age, race, or diabetes status.
The Ontario Institute for Cancer Research (OICR) reported investments in three new Ontario companies aimed at bringing promising anticancer technologies to market.
Roche honored 12 doctoral students and two professors with the company’s Excellence in Chemistry Award for research accomplishments in the field of organic chemistry.
Eli Lilly and Company has signed agreements with Care Capital and NovaQuest Capital to establish BioCritica Inc., a privately-held biotechnology company.
GenKyoTex has raised CHF18 million ($20.4 million), which will be used for the clinical development of the lead compound GKT137831 for the treatment of diabetic nephropathy.